drugset / Trial / NCT07699120

Evaluation of BRC-002 Safety, Tolerability, Pharmacokinetics, and Food Effects in Healthy Participants

NCT07699120 ↗

Phase 1 Enrolling by invitation 50 enrolled Biopharmaceutical Research Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and tolerability of BRC-002, an investigational botanical drug from cannabis, in healthy adults. The study will also assess how the body processes BRC-002 and whether taking it with food affects how it is absorbed or metabolized. The results of this study will help support further clinical development of BRC-002 and guide dose selection in patient populations.

Timeline

Start
2026-06-15
Primary completion
2026-10
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BRC-002 Unknown — Oral

Indications

No indication recorded.